My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dynavax Technologies Corporation - Common Stock (NQ:DVAX)

9.800 -0.130 (-1.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dynavax Technologies Corporation - Common Stock

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom
From Deep Track Capital, LP
Via Business Wire
Glass Lewis Recommends Shareholders Support Deep Track’s Case for Board Change at Dynavax Technologies
From Deep Track Capital, LP
Via Business Wire
Deep Track Capital Comments on ISS Recommendation
From Deep Track Capital, LP
Via Business Wire
Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting
From Deep Track Capital, LP
Via Business Wire
Deep Track Capital Releases Investor Presentation on Dynavax Technologies
From Deep Track Capital, LP
Via Business Wire
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
From Deep Track Capital, LP
Via Business Wire
Deep Track Capital Comments on Dynavax Technologies’ Rejection of Most Recent Settlement Offer
From Deep Track Capital, LP
Via Business Wire
Deep Track Capital Sends Letter to Dynavax Technologies’ Board of Directors
From Deep Track Capital, LP
Via Business Wire
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting
From Deep Track Capital, LP
Via Business Wire
Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)
From Glancy Prongay & Murray LLP
Via Business Wire
Lantheus Appoints Julie Eastland as New Board Member
From Lantheus Holdings, Inc.
Via GlobeNewswire
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
From Clover Biopharmaceuticals
Via GlobeNewswire
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
From Clover Biopharmaceuticals
Via GlobeNewswire
Clover Provides Update on 2022 Corporate Milestones
From Clover Biopharmaceuticals
Via GlobeNewswire
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from... 
Via FinancialNewsMedia
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
Palm Beach, FL – October 20, 2021 – FinancialNewsMedia.com News Commentary – Recently, scientific reports have shown that a universal coronavirus vaccine that protects against COVID-19 causing... 
Via FinancialNewsMedia
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.